-
1.发明授权Optimized DNA sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins 有权优化抗体的DNA序列，以提高细菌表达的抗体融合蛋白的质量和产量公开(公告)号：US08530637B2
公开(公告)日：2013-09-10
申请号：US12985542
申请日：2011-01-06
IPC分类号： C07H21/04
CPC分类号： C07K16/32 , A61K31/7088 , C07K14/21 , C07K2317/622 , C07K2319/00 , C07K2319/55
摘要： Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
摘要翻译： 本发明的目的是编码scFv（FRP5）抗体片段的优化的DNA序列。 该新型序列防止在scFv（FRP5）-ETA融合蛋白以及可能还有其它细菌表达的scFv（FRP5）融合蛋白的上下文中产生不需要的副产物。 通过交换不同的密码子修饰scFv（FRP5）-ETA的scFv（FRP5）结构域的DNA序列，从而防止蛋白质翻译的另外可能的内部启动。
-
2.发明申请OPTIMIZED DNA AND PROTEIN SEQUENCE OF AN ANTIBODY TO IMPROVE QUALITY AND YIELD OF BACTERIALLY EXPRESSED ANTIBODY FUSION PROTEINS 有权抗体的优化DNA和蛋白质序列提高细菌表达抗体融合蛋白的质量和产量公开(公告)号：US20090018079A1
公开(公告)日：2009-01-15
申请号：US12170623
申请日：2008-07-10
IPC分类号： A61K38/00 , C07K14/00 , C12N15/11 , C12N15/00 , A61P31/00 , A61K31/7088 , C12N1/20 , C12P21/04
CPC分类号： C07K16/32 , A61K31/7088 , C07K14/21 , C07K2317/622 , C07K2319/00 , C07K2319/55
摘要： Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
摘要翻译： 本发明的目的是编码scFv（FRP5）抗体片段的优化的DNA序列。 该新型序列防止在scFv（FRP5）-ETA融合蛋白以及可能还有其它细菌表达的scFv（FRP5）融合蛋白的上下文中产生不需要的副产物。 通过交换不同的密码子修饰scFv（FRP5）-ETA的scFv（FRP5）结构域的DNA序列，从而防止蛋白质翻译的另外可能的内部启动。
-
3.发明申请Optimized DNA Sequence Of An Antibody To Improve Quality And Yield Of Bacterially Expressed Antibody Fusion Proteins 有权抗体优化DNA序列，提高细菌表达抗体融合蛋白的质量和产量公开(公告)号：US20110105742A1
公开(公告)日：2011-05-05
申请号：US12985542
申请日：2011-01-06
IPC分类号： C07H21/04
CPC分类号： C07K16/32 , A61K31/7088 , C07K14/21 , C07K2317/622 , C07K2319/00 , C07K2319/55
摘要： Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
摘要翻译： 本发明的目的是编码scFv（FRP5）抗体片段的优化的DNA序列。 该新型序列防止在scFv（FRP5）-ETA融合蛋白以及可能还有其它细菌表达的scFv（FRP5）融合蛋白的上下文中产生不需要的副产物。 通过交换不同的密码子修饰scFv（FRP5）-ETA的scFv（FRP5）结构域的DNA序列，从而防止蛋白质翻译的另外可能的内部启动。
-
4.发明授权Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins 有权优化抗体的DNA和蛋白质序列，以改善细菌表达的抗体融合蛋白的质量和产量公开(公告)号：US07887801B2
公开(公告)日：2011-02-15
申请号：US12170623
申请日：2008-07-10
IPC分类号： A61K39/00
CPC分类号： C07K16/32 , A61K31/7088 , C07K14/21 , C07K2317/622 , C07K2319/00 , C07K2319/55
摘要： Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
摘要翻译： 本发明的目的是编码scFv（FRP5）抗体片段的优化的DNA序列。 该新型序列防止在scFv（FRP5）-ETA融合蛋白以及可能还有其它细菌表达的scFv（FRP5）融合蛋白的上下文中产生不需要的副产物。 通过交换不同的密码子修饰scFv（FRP5）-ETA的scFv（FRP5）结构域的DNA序列，从而防止蛋白质翻译的另外可能的内部启动。
-
5.发明申请METHOD OF DECREASING CYTOTOXIC SIDE-EFFECTS AND IMPROVING EFFICACY OF IMMUNOCONJUGATES 有权降低细胞毒副作用的方法和提高免疫球蛋白的效率公开(公告)号：US20090181038A1
公开(公告)日：2009-07-16
申请号：US12342180
申请日：2008-12-23
申请人： Gregor Schulz , Christoph Bruecher , Frank Osterroth , Steffen Zeng , Christoph Uherek , Silke Aigner , Benjamin Daelken , Markus Ruehle , Elmar Kraus
发明人： Gregor Schulz , Christoph Bruecher , Frank Osterroth , Steffen Zeng , Christoph Uherek , Silke Aigner , Benjamin Daelken , Markus Ruehle , Elmar Kraus
IPC分类号： A61K39/44
CPC分类号： C07K16/2896 , A61K39/39558 , A61K47/48561 , A61K47/48569 , A61K47/48723 , A61K47/6849 , A61K47/6851 , A61K47/6891 , A61K2039/505 , A61K2300/00 , B82Y5/00 , C07K2317/24 , C07K2317/34
摘要： Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.
摘要翻译： 公开了用于改善免疫缀合物的靶向特别是肿瘤靶向的方法，组合物和试剂盒。 该方法和组合依赖于也表达免疫共轭靶标的非靶细胞的螯合。 公开了以各种方式封存那些非目标细胞。 方法，组合物和试剂盒允许非靶细胞的适当螯合，同时保持免疫缀合物对靶细胞的高度有效性。
-
6.发明授权公开(公告)号：US09446146B2
公开(公告)日：2016-09-20
申请号：US12342815
申请日：2008-12-23
申请人： Benjamin Daelken , Christoph Uherek , Kenneth Anderson , Teru Hideshima , Christoph Bruecher , Frank Osterroth , Silke Aigner , Matthias Germer
发明人： Benjamin Daelken , Christoph Uherek , Kenneth Anderson , Teru Hideshima , Christoph Bruecher , Frank Osterroth , Silke Aigner , Matthias Germer
CPC分类号： A61K47/48561 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6867 , A61K2039/505 , C07K16/2896 , C07K2317/34 , C07K2317/73 , C07K2317/92
摘要： Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.
摘要翻译： 公开了对CD138具有特异性的免疫缀合物，其降低表达CD138的肿瘤细胞与基质细胞的粘附性及其使用方法。 这种粘附性降低使得肿瘤细胞不仅对免疫缀合物敏感，而且对其它试剂，特别是细胞毒性剂也是敏感的。
-
7.发明申请HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 有权用于治疗系统性红斑狼疮（SLE）的人类抗IL10抗体公开(公告)号：US20120321618A1
公开(公告)日：2012-12-20
申请号：US13512780
申请日：2010-11-30
申请人： Frank Osterroth , Christoph Uherek , Christoph Bruecher , Peter Röttgen , Benjamin Daelken , André Engling , Chantal Zuber , Niklas Czeloth , Andrea Wartenberg-Demand , Marcus Gutscher , Judith Wessels-Kranz
发明人： Frank Osterroth , Christoph Uherek , Christoph Bruecher , Peter Röttgen , Benjamin Daelken , André Engling , Chantal Zuber , Niklas Czeloth , Andrea Wartenberg-Demand , Marcus Gutscher , Judith Wessels-Kranz
IPC分类号： A61K39/395 , C12N15/62 , C12N15/85 , A61P19/00 , C12N5/071 , G01N33/566 , C12N5/10 , C07K16/46 , C12P21/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92 , G01N33/6869
摘要： Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.
摘要翻译： 本发明提供了能够结合白细胞介素-10（Th-10）的人源化或嵌合抗体或其片段，其中所述抗体或其片段能够在不存在不能耐受的增加的细胞因子的情况下施用于受试者 炎性细胞因子。 还提供了涉及使用抗体或其片段的治疗方法。
-
8.发明申请METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS 有权用于改善CD138表达肿瘤细胞靶向的方法和试剂公开(公告)号：US20090169570A1
公开(公告)日：2009-07-02
申请号：US12342815
申请日：2008-12-23
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K47/48561 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6867 , A61K2039/505 , C07K16/2896 , C07K2317/34 , C07K2317/73 , C07K2317/92
摘要： Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.
摘要翻译： 公开了对CD138具有特异性的免疫缀合物，其降低表达CD138的肿瘤细胞与基质细胞的粘附性及其使用方法。 这种粘附性降低使得肿瘤细胞不仅对免疫缀合物敏感，而且对其它试剂，特别是细胞毒性剂也是敏感的。
-
公开(公告)号：US09550831B2
公开(公告)日：2017-01-24
申请号：US12880768
申请日：2010-09-13
申请人： Silke Aigner , Matthias Germer , Frank Osterroth , Christoph Uherek , Elmar Kraus , Andrea Wartenberg-Demand , Daniele Wolf , Sibylle Kaiser , Juergen Lindner , Christoph Bruecher , Benjamin Daelken , Gregor Schulz
发明人： Silke Aigner , Matthias Germer , Frank Osterroth , Christoph Uherek , Elmar Kraus , Andrea Wartenberg-Demand , Daniele Wolf , Sibylle Kaiser , Juergen Lindner , Christoph Bruecher , Benjamin Daelken , Gregor Schulz
IPC分类号： A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2812 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2317/92
摘要： The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.
摘要翻译： 本发明提供了用于治疗自身免疫疾病的药物组合物，其包含药学上可接受的载体和能够激活CD4 + CD25 +调节性T细胞的试剂，其中该组合物最多每3天施用于受试者。
-
10.发明授权Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE) 有权用于治疗系统性红斑狼疮（SLE）的人源化抗IL 10抗体公开(公告)号：US08956607B2
公开(公告)日：2015-02-17
申请号：US13512712
申请日：2010-11-30
申请人： Frank Osterroth , Christoph Uherek , Christoph Bruecher , Peter Röttgen , Benjamin Daelken , André Engling , Chantal Zuber , Niklas Czeloth
发明人： Frank Osterroth , Christoph Uherek , Christoph Bruecher , Peter Röttgen , Benjamin Daelken , André Engling , Chantal Zuber , Niklas Czeloth
CPC分类号： C07K16/244 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92 , G01N33/6869
摘要： Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor α(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.
摘要翻译： 提供能够结合白细胞介素-10（IL-10）的人源化或嵌合抗体或其片段，其中所述抗体或其片段：（i）结合与IL-10受体α相同的IL-10区域（ IL-10Ra），并且当IL-10与IL-10受体结合时不能结合IL-10; 和（ii）通过结合包含两个单体的残基的不连续表位与同型二聚体形式的IL-10结合。 进一步提供涉及使用抗体或其片段的相关产物和方法。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.032 秒)
